Xerenex Kidney Treatment: A Game Changer for Keryx Biopharmaceuticals
GO and read the article by Marivic Cabural on The Motley Fool.
'There is also a possibility for Keryx Pharmaceuticals to establish a partnership with DaVita Healthcare Partners (NYSE: DVA), one of the leading providers of dialysis treatment for patients with ESRD. DaVita provides kidney dialysis treatment to 142,000 patients with chronic kidney failure. Eighty nine percent (89%) of its patient are covered under government-based healthcare programs, particularly Medicare. Since, Zerernx offers huge savings due to reduced use for IV iron and ESA, dialysis treatment providers such as DaVita would consider switching its phosphate binder treatments to patients. Bentsur pointed out that Sanofi’s generic Renvela doesn’t have the capacity to compete with the amount of cost savings offered by Zenerex.'
Guys although the article is correct and positive it doesn't say anything we didn't know before. Until a partnership materializes all this is silly pumping. Don't confuse people's expectations. If we get news of a partnership that is a big deal. An article saying how great the company and drug are will not move the stock significantly. Sadly I was confused into thinking a partnership announcement was imminent based on these posts. That is by what the DVA article said at all.